• Tolera Therapeutics Inc., of Cleveland, raised $8 million in a Series A round led by Triathlon Medical Ventures, of Cincinnati, with participation from the Southwest Michigan First Life Science Fund, of Kalamazoo, Mich., and Hopen Therapeutics Inc., of Grand Rapids, Mich. Tolera, which was spun out of Cleveland Clinic Innovations in January 2007, is focused on developing immunotherapeutics directed at the transplantation, oncology and autoimmune disease markets. In connection with the financing, Suzette Dutch, of Triathlon, will join the company's board.